LCN2 and acute kidney injury: Our local NGAL implementation and its associated audit was expressly designed toevaluate the ability of this novel AKI biomarker, and its combination withtraditional urine chemistries, to help clinicians at bedside, when facing complexAKI cases, to optimize the differential diagnostic assessment in a real-lifesetting.